AveXis, Inc. (NASDAQ:AVXS) had its price target cut by investment analysts at Bank of America Corporation from $115.00 to $112.00 in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Bank of America Corporation’s target price suggests a potential upside of 16.92% from the stock’s current price.
Other research analysts have also issued research reports about the stock. Sanford C. Bernstein began coverage on shares of AveXis in a report on Thursday, July 27th. They issued an “outperform” rating and a $108.00 price target on the stock. Royal Bank Of Canada restated a “hold” rating and issued a $92.00 price target on shares of AveXis in a report on Thursday, November 2nd. Evercore ISI began coverage on shares of AveXis in a report on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 price target on the stock. Wells Fargo & Company restated an “outperform” rating and issued a $134.00 price target (up previously from $89.00) on shares of AveXis in a report on Tuesday, September 5th. Finally, Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $108.26.
Shares of AveXis (AVXS) opened at $95.79 on Friday. AveXis has a 12-month low of $44.68 and a 12-month high of $108.27.
AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the business earned ($0.87) EPS. equities research analysts anticipate that AveXis will post -5.55 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Bank of America Corporation Lowers AveXis, Inc. (AVXS) Price Target to $112.00” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/13/bank-of-america-corporation-lowers-avexis-inc-avxs-price-target-to-112-00.html.
In other news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $97.25, for a total transaction of $173,105.00. Following the sale, the vice president now owns 1,780 shares in the company, valued at $173,105. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The disclosure for this sale can be found here. Insiders have sold 35,340 shares of company stock worth $3,559,683 in the last quarter. Insiders own 18.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of AveXis during the third quarter valued at approximately $116,000. Botty Investors LLC purchased a new stake in shares of AveXis during the second quarter valued at approximately $123,000. Ameritas Investment Partners Inc. increased its stake in shares of AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after buying an additional 1,622 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of AveXis in the third quarter worth $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new stake in shares of AveXis in the third quarter worth $203,000. Institutional investors own 94.96% of the company’s stock.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.